All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Treatment of Dural Solitary Fibrous Tumor/Hemangiopericytoma of Spine with a New Tyrosine Kinase Inhibitor Anlotinib Hydrochloride: A Case Report

Author(s): Wei Luan, Lan Yu, Zheng Liu, Wen-Xin Li

The treatment options for high-grade dual Hemangiopericytoma (HPC) of the Central Nervour System (CNS) include surgical resection, radiation, and chemotherapy. Target therapy has no been reported in the literature. The choice of pharmaceutical target treatment for the Central Nervous (CNS) hemangiopericytoma is very limited. The pathogenesis of hemangiopericytoma is thought to relate to tumor angiogenesis and high expression of Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF) of tumor cells. The Tyrosine Kinase Inhibitor (TKI) that is proven to have potent inhibitory effects on VEGFR, PDGFR, FGFR, and c-Kit at the same time would be the ideal choice of the targeted therapy for hemangiopericytoma. In this article, we report a 29-year-old man with advanced high-grade hemangiopericytoma arising from the dura of the spinal cord received targeted therapy of this newly approved tyrosinase inhibitor Anlotinib Hydrochloride, which has the capability of multiple target points. Two weeks after the treatment, the size of the tumor was reduced significantly based on image analysis, and the patient’s compressive symptoms were improved considerably. This is the first case of high-grade hemangiopericytoma successfully managed with these newly approve tyrosine kinase inhibitors, a large scale clinical research on the targeted therapy of this tumor would be necessary to further understanding the pharmaceutical mechanisms of Anlotinib Hydrochloride on the tumor suppression of CNS hemangiopericytoma.


PDF